OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer ...

Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's ...

Brenna Huckaby, a Louisiana native, turned her tragedy of being diagnosed with osteosarcoma and having her leg amputated at ...

Niclosamide is an old antiparasitic with documented anticancer activity in laboratory models, but its clinical use for cancer has been limited by poor solubility and bioavailability. The authors ...

Osteosarcoma is a malignant neoplasm of the bone and is the most common histological form of primary bone cancer. It is most prevalent in children and young adults, as it is associated with the ...

A major driver of the bone cancer osteosarcoma has been discovered by researchers from UCL, EMBL EBI and the Royal National Orthopaedic Hospital, providing insights that could help to predict cancer ...

The histopathological features of osteosarcoma vary widely, often leading to diagnostic difficulties particularly when there is little evidence of osteoid formation. The report describes the ...

Scientists at Princess Margaret Cancer Centre have discovered that blocking the master regulator of bone renewal stops osteosarcoma - the most common primary bone cancer in children and teens, and the ...

Legislation to fund pediatric cancer research passed unanimously out of an Iowa House subcommittee Thursday after lawmakers ...

OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, is honored ...